Announcements Trials

Browse Landscape

Phase

Phase NA 1 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1129 Carcinoma, Non-Small-Cell Lung 718 Neoplasms 546 Prostatic Neoplasms 505 Colorectal Neoplasms 439 Multiple Myeloma 338 Lung Neoplasms 310 Neoplasm Metastasis 289 Leukemia, Myeloid, Acute 263 Stomach Neoplasms 248 Carcinoma, Hepatocellular 246 Ovarian Neoplasms 225 Rectal Neoplasms 211 Colonic Neoplasms 204 Lymphoma, Follicular 200 Lymphoma 199 Leukemia 190 Uterine Cervical Neoplasms 181 Head and Neck Neoplasms 174 Pancreatic Neoplasms 172 Lymphoma, Non-Hodgkin 167 Leukemia, Lymphocytic, Chronic, B-Cell 166 Lymphoma, Large B-Cell, Diffuse 163 Recurrence 162 Melanoma 158 Precursor Cell Lymphoblastic Leukemia-Lymphoma 154 Squamous Cell Carcinoma of Head and Neck 147 Pain 141 Urinary Bladder Neoplasms 139 Brain Neoplasms 133

Interventions

telotristat ethyl 1 lanreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Interventional × Carcinoid Heart Disease × Clear all

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡